Clinical Trial

PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer

Study acronym: PORTEC-4a
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 11, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is prospective, multicenter, randomised phase III trial among women with endometrial cancer with high-intermediate risk features to investigate the role of an integrated clinicopathological and molecular risk profile to determine if participants should receive no adjuvant therapy, vaginal brachytherapy or external beam radiotherapy based on a favourable, intermediate or unfavourable profile as compared to standard adjuvant vaginal brachytherapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2018-03-16; most recent amendment 2023-10-10.
Status change: Recruiting → Active, Not Recruiting 2023-10-10
Trial Details
NCT Number NCT03469674
Lead Sponsor Leiden University Medical Center
Collaborators: Dutch Cancer Society, Comprehensive Cancer Centre The Netherlands
Conditions Endometrial Cancer Stage I, Endometrial Cancer Stage II
Enrollment 550 participants
Start Date 2016-06-10
Primary Completion 2024-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-10-11